Journal of Psychoactive Drugs
November 10, 2024
Jake Scarcella, Jeffrey MacDaniels, Lucinda Coffin et al.
1 citation
Esketamine, the isolated S-enantiomer of ketamine, has been a recent breakthrough as a non-monoaminergic treatment for treatment-resistant depression (TRD). This case report explores a rare adverse event in a 41-year-old female with TRD, who, despite experiencing significant depressive improvement with esketamine, encountered a severe dissociative episode accompanied by hallucinogenic-like...
Journal of Psychoactive Drugs
November 6, 2024
Rotem Petranker, Valentyn Sobolenko, Zeina Beidas et al.
9 citations
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193...
Journal of Psychoactive Drugs
November 6, 2024
Aleksandra Barstowe, Petri Kajonius
8 citations
Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. However, the evaluation of masking success is rarely reported in trials. The objective of the present systematic review was to evaluate placebo-control and masking in studies exploring psychedelic-assisted therapy. Nine (k = 9) studies dating between...
Journal of Psychoactive Drugs
November 4, 2024
Aurore Bezo, Bruno Romeo, Y Le Strat et al.
1 citation
The aim of this study was to explore the perception of psychedelics within the medical population. Participants were asked by questionnaire about the potential of abuse, the somatic and psychiatric complications, and the risks of self-harm and aggression associated with the use of psychedelics using Likert Scales. A total of 407 participants were included. In our sample, the following means...
Journal of Psychoactive Drugs
October 29, 2024
Taynara Simão Matos, Flávia Da Silva Zandonadi, Alex Aparecido Rosini Silva et al.
Ayahuasca is a brew traditionally prepared with a mixture of Psychotria viridis leaves and Banisteriopsis caapi vine and has demonstrated therapeutic properties for depression. Knowledge of the brew composition is important to improve the therapeutic potential and decrease side effects if ayahuasca becomes an option for refractory depression treatment. Ultra-high performance liquid...
Journal of Psychoactive Drugs
October 23, 2024
Jessica L Maples-Keller, Courtland S Hyatt, Nathaniel L Phillips et al.
2 citations
3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research suggests a change in personality traits may be a factor in treatment response. Most prior research on MDMA and personality has focused on cross-sectional comparisons of MDMA users and non-users; as such, well-controlled research assessing personality and...
Journal of Psychoactive Drugs
October 15, 2024
Jamie E Parnes, Mitch Earleywine
Despite increasing interest in psychedelics and their potential therapeutic effects, research on inhaled N,N-Dimethyltryptamine (DMT) remains limited. Inhaled DMT has a reputation for rapid, dramatic onset and a brief duration, but correlates of use frequency remain poorly understood. A sample recruited from relevant internet sites, including nearly 400 people who had inhaled DMT, reported...
Journal of Psychoactive Drugs
September 19, 2024
Anne Baker, Niloufar Pouyan, Julie Barron et al.
9 citations
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report naturalistic psychedelic use with so-called "underground" practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives of these practitioners. We conducted an anonymous online survey of individuals who...
Journal of Psychoactive Drugs
September 13, 2024
Ar Wilson-Poe, Ka Hoffman, Jb Luoma et al.
9 citations
Emerging legal frameworks in Oregon and Colorado license facilitators to support adults receiving psychedelic services. The current legal frameworks are silent regarding facilitators' personal experience with psychedelics. An e-Delphi process recruited 36 experts with at least 5 years' experience facilitating psilocybin experiences in ceremonial settings, indigenous practices, or clinical...
Journal of Psychoactive Drugs
September 12, 2024
Katinka Hooyer, Rachel Yehuda, Alan K. Davis et al.
4 citations
We sought to identify patterns of psychedelic use among United States military veterans, compare demographic variables and perspectives of those who did and did not report use, and characterize benefits and adverse outcomes associated with use. Respondents (N = 426) were recruited to complete an online cross-sectional survey. Approximately one-half (51%) reported using psychedelics. Most did so...
Journal of Psychoactive Drugs
September 10, 2024
Nilubon Thaoboonruang, Manupat Lohitnavy, Ornrat Lohitnavy
11 citations
Psilocybin, a major indole alkaloid found in magic mushrooms (Psilocybe cubensis), has recently drawn attention as a breakthrough therapy to treat major depressive disorder. This review aimed to summarize and identify knowledge gaps concerning their pharmacokinetic characteristics of psilocybin and its active metabolite, psilocin. Original studies related to pharmacokinetics of psilocybin...
Journal of Psychoactive Drugs
July 10, 2024
Ashutosh Bhave
10 citations
In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psilocybin mushrooms are considered the...
Journal of Psychoactive Drugs
July 3, 2024
Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al.
5 citations
Treating cannabis use disorder remains a significant challenge in the field of addiction medicine. Some recent studies point to psychedelic-assisted psychotherapy as a potential treatment option for substance use disorders. The objective of this study was therefore to explore the impact of naturalistic psychedelic experiences on cannabis use and psychological flexibility. An online...
Journal of Psychoactive Drugs
June 29, 2024
Dima Audi, Shorouk Hajeer, Marie-belle Saab et al.
ABSTRACT Cannabis is one of the most commonly utilized recreational drugs. However, increasing evidence from the literature suggests harmful implications on cognition. Thus, the main aim of the current review is to summarize literature findings pertaining to the impact of cannabis on neurocognitive skills, focusing on the imaging biomarkers provided by MRI. Two reviewers navigated the...
Journal of Psychoactive Drugs
June 27, 2024
T. Mastelić, Tonka Borovina Marasović, M. Žuljević et al.
ABSTRACT For some time now, there has been an increased interest in psychedelics among scientists and mental health experts. Given that experts introduce therapy and advise patients, it is important to know their views. Therefore, the aim of our research was to examine and compare the attitudes of psychiatrists and psychologists toward psychedelics. We were interested in how they are formed and...
Journal of Psychoactive Drugs
June 21, 2024
Peter Kenneth Gillman, Brian S. Barnett, Curtis J. Koons et al.
9 citations
Data on medication interactions with psychedelics are limited. Here we present what may be the first published report of a hypertensive emergency following the combination of psilocybin mushrooms with a monoamine oxidase inhibitor (MAOI). A 42-year-old man with treatment-resistant major depressive disorder took 1 g of Psilocybe cubensis mushrooms, while prescribed tranylcypromine,...
Journal of Psychoactive Drugs
May 7, 2024
Sandeep M. Nayak, Sydney H White, Samantha Hilbert et al.
18 citations
Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind perception, 2) non-naturalistic beliefs, and 3) Atheist-Believer status (e.g. believer, agnostic, or nonbeliever). We conducted a prospective longitudinal study among participants (N = 657) who planned to have a psilocybin experience outside a...
Journal of Psychoactive Drugs
May 2, 2024
Dave Rojas, Diane C Zelman, Alexander O Hauson et al.
2 citations
Black, Indigenous, and People of Color (BIPOC), and other minoritized populations are insufficiently represented in research on therapeutic psychedelics. This research was a phenomenological qualitative exploration of a culturally diverse (Hispanic, African American, Asian, Native American, biracial, or LGBTQIA+) and low-income sample of 15 individuals receiving ketamine-assisted psychotherapy...
Journal of Psychoactive Drugs
February 10, 2024
Alyssa F. Harlow, Peter S. Hendricks, Adam M. Leventhal et al.
6 citations
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were...
Journal of Psychoactive Drugs
January 22, 2024
Estelle Miller, Vida Bojovic, Olivia Maddren et al.
ABSTRACT “Microdosing,” defined as the consumption of small, sub-hallucinogenic quantities of psychedelic drugs, has gained recent popularity. Microdosing is a relatively new concept, therefore no scientific recommendations exist on how to prepare and consume microdoses. Many consumers obtain microdosing information online. Few studies have investigated the content of this information; thus,...
Journal of Psychoactive Drugs
January 15, 2024
Oliver Rumle Hovmand, Mathias Ebbesen Jensen, Tobias Søgaard Juul et al.
6 citations
Research suggests positive changes in both well-being and psychiatric symptoms following a psychedelic experience. One explanation may be the ability of psychedelic compounds to occasion mystical-type experiences. The Revised Mystical Experiences Questionnaire (MEQ30) is designed to assess the intensity and quality of such experiences. We examined the validity, reliability, and factor structure...
Journal of Psychoactive Drugs
2024
Daniel J. Kruger, Carlton Cb Bone, Meredith C Meacham et al.
9 citations
There is a growing interest in semi-synthetic cannabinoids, including THC-O-acetate (THC-Oac). Some cannabis marketers and users have claimed that THC-Oac produces psychedelic effects; the current study is the first to examine this claim. Researchers developed an online survey for THC-Oac consumers based on previous cannabis and psychedelic use surveys and in consultation with the moderator of...
Journal of Psychoactive Drugs
2024
Julia M.k. Freind, Fernando R. Beserra, Bruno S Menezes et al.
9 citations
Depression is one of the most prevalent mental health disorders globally, causing severe emotional suffering, reducing life expectancy and increasing the risk of suicide. Recently, the use of dissociative psychedelic substances such as ketamine and esketamine for depressive disorders has expanded treatment options. We sought to analyze, through a systematic review, the existing protocols for...
Journal of Psychoactive Drugs
2024
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira et al.
7 citations
Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe...
Journal of Psychoactive Drugs
2024
Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al.
4 citations
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...